FR3144506A1 - COMBINATION OF ACTIVE INGREDIENTS WITH PANTETHEINE S SULFONATE FOR A PURIFYING ACTION - Google Patents

Abstract

The present invention relates to a cosmetic composition comprising, in a physiologically acceptable medium: - calcium pantetheine sulfonate, and - at least 2 ingredients chosen from the group consisting of: • hydroxypropyl cyclodextrin, • phytosphingosine, • hydrogenated lecithin • sodium carrageenan, and • an extract of Porphyridium cruentum.

Description

COMBINATION OF ACTIVE INGREDIENTS WITH PANTETHEINE S SULFONATE FOR A PURIFYING ACTION Field of the invention

The present invention relates to a cosmetic composition, in particular a cosmetic care composition intended for the hygienic cleaning and/or disinfection of keratin materials, in particular of the skin, in particular the skin of the face and/or hands.

State of the art

The skin is the first barrier of the human body, in contact with various exogenous factors including pathogens such as bacteria and viruses.

The last two years have seen the advent of reinforced health measures such as hand washing and the use of hydroalcoholic gel before and after any contact, or wearing a mask to prevent the spread and contamination by respiratory viruses such as SARS-Cov2.

Respiratory viruses such as SARS-Cov2 and the influenza virus are transmitted in humans by multiple routes which mainly include the emission and inhalation through the nose and mouth of droplets and aerosols containing the particles viral, but also indirect contamination through contact of hands with inanimate surfaces or various supports (called fomites) on which droplets and aerosols containing viral particles are deposited (Guo et al., 2020).

Thus, droplets contaminated by the virus can be deposited on the surface of various objects, fabrics, coins, banknotes, catheters and other materials and supports used in a hospital environment, which can be touched by the skin of the hands which, in turn, will come into contact with the mucous membranes of the mouth and nose which will mediate the entry of the virus and infection of the patient. Recent studies have shown that the vast majority of respiratory viruses, such as coronaviruses, influenza and rhinoviruses, can persist on inanimate surfaces for a few days, leading to the conclusion that the transmission of influenza and SARS -CoV-2 by fomites is likely to take place and participate in the infectious process (Chan et al., 2020; Ren et al., 2020).

Given that contact transmission is a significant risk factor in the spread of influenza and SARS-CoV-2, this highlights the need to practice good hand hygiene to prevent the transmission of these pathogens. However, while frequent hand washing can be easily applied, this is not the case for the face which remains exposed. Furthermore, the frequent use of disinfectants is a major cause of skin irritation, particularly among healthcare personnel (Lan et al., 2020).

These facts prompted the Applicant to study the design and development of a cosmetic composition which could be applied to the face and/or hands and which would present a cleansing and/or disinfectant activity for the skin and/or a preventive activity. and/or reducing contamination and viral infection, but which is gentle and non-irritating upon application and preserves the skin's lipid film.

Furthermore, this composition would have the advantage of having persistence, allowing less frequent use of disinfectants and consequently reducing skin irritation.

Phytosphingosine, a precursor of ceramides, is present in human skin. The reduction in ceramides leads to an increase in dryness of the skin.

Surprisingly, the Applicant was able to demonstrate in vitro that certain active ingredients, such as calcium pantetheine sulfonate advantageously in association with hydroxypropyl cyclodextrin, and/or phytosphingosine, and/or hydrogenated lecithin, and/or sodium carrageenan, and/or an extract of Porphyridium cruentum , are effective in inactivating viral particles and significantly reducing their infectious potential while having improved cosmetic properties (softness, preserved lipid film).

According to a first aspect, the invention relates to a cosmetic composition comprising, in a physiologically acceptable environment:

- calcium pantetheine sulfonate, and

- at least 2 ingredients chosen from the group consisting of:

• hydroxypropyl cyclodextrin,

• phytosphingosine,

• hydrogenated lecithin,

• sodium carrageenan, and

• an extract of Porphyridium cruentum.

Preferably, said cosmetic composition is characterized in that it comprises, in a physiologically acceptable medium:

- calcium pantetheine sulfonate,

- phytosphingosine,

- hydrogenated lecithin, and

- at least 1 ingredient chosen from the group consisting of:

• hydroxypropyl cyclodextrin,

• sodium carrageenan, and

• an extract of Porphyridium cruentum .

More preferably, said cosmetic composition is characterized in that it comprises, in a physiologically acceptable medium:

- calcium pantetheine sulfonate,

- hydroxypropyl cyclodextrin,

- phytosphingosine,

- hydrogenated lecithin,

- carrageenan sodium, and

- an extract of Porphyridium cruentum .

Preferably, said cosmetic composition is in the form of a cream, oil-in-water or water-in-oil emulsion or multiple emulsion, solution, oil, suspension, gel, milk, lotion, or serum.

Preferably, said cosmetic composition further comprises at least one cosmetic adjuvant chosen from the group consisting of antioxidant agents, emollient agents, moisturizing agents, anti-aging agents and mixtures thereof.

Preferably, said cosmetic composition is characterized in that it comprises:

- calcium pantetheine sulfonate in a content ranging from 0.01% to 8% by weight relative to the total weight of the composition,

- at least 2 ingredients chosen from the group consisting of:

• phytosphingosine in a content ranging from 0.001% to 5% by weight relative to the total weight of the composition,

• Hydrogenated lecithin in a content ranging from 0.01% to 10% by weight relative to the total weight of the composition,

• hydroxypropyl cyclodextrin in a content ranging from 0.01% to 5% by weight relative to the total weight of the composition,

• carrageenan sodium in a content ranging from 0.001% to 5% by weight relative to the total weight of the composition, and

• an extract of Porphyridium cruentum in a content ranging from 0.001% to 5% by weight relative to the total weight of the composition.

According to another aspect, the present invention relates to a cosmetic process for cleansing and/or purifying keratin materials, in particular of the skin, comprising the application to said keratin materials of at least one layer of cosmetic composition such as defined above.

Preferably, said cosmetic process is a cleansing and/or purifying hand care process.

According to another aspect, the present invention involves the use of a combination of ingredients as defined above, in particular the combination of:

- calcium pantetheine sulfonate, and

- at least 2 ingredients chosen from the group consisting of:

• hydroxypropyl cyclodextrin,

• phytosphingosine,

• hydrogenated lecithin,

• sodium carrageenan, and

• an extract of Porphyridium cruentum ,

or preferably the association comprising:

- calcium pantetheine sulfonate,

- phytosphingosine,

- hydrogenated lecithin, and

- at least 1 ingredient chosen from the group consisting of:

• hydroxypropyl cyclodextrin,

• sodium carrageenan, and

• an extract of Porphyridium cruentum ,

or preferably the association comprising:

- calcium pantetheine sulfonate,

- hydroxypropyl cyclodextrin,

- phytosphingosine,

- hydrogenated lecithin,

- carrageenan sodium, and

- an extract of Porphyridium cruentum

as an active association for the hygienic cleaning and/or disinfection of keratin materials, in particular of the skin.

Preferably, the use of calcium pantetheine sulfonate, or of a cosmetic composition comprising it, is for the hygienic cleaning and/or disinfection of keratin materials, in particular of the skin. In particular, for hygienic cleaning and/or disinfection of hands.

Description of figures

Study of the antiviral effect of calcium pantetheine sulfonate in cell culture.

Study of the antiviral effect of calcium pantetheine in association with different combinations of active ingredients used according to the invention on a human skin model.

Study of the maintenance of the antiviral effect over time.

Detailed description of the invention

According to a first aspect, the present invention relates to a cosmetic composition comprising, in a physiologically acceptable medium:

- calcium pantetheine sulfonate, and

- at least 2 ingredients chosen from the group consisting of:

• hydroxypropyl cyclodextrin,

• phytosphingosine,

• hydrogenated lecithin,

• sodium carrageenan, and

• an extract of P orphyridium cruentum .

According to a particular embodiment, said cosmetic composition comprises, in a physiologically acceptable medium:

- calcium pantetheine sulfonate, and

- at least 3 ingredients chosen from the group consisting of:

• hydroxypropyl cyclodextrin,

• phytosphingosine,

• hydrogenated lecithin,

• sodium carrageenan, and

• an extract of Porphyridium cruentum .

According to a particular embodiment, said cosmetic composition comprises, in a physiologically acceptable medium:

- calcium pantetheine sulfonate, and

- at least 4 ingredients chosen from the group consisting of:

• hydroxypropyl cyclodextrin,

• phytosphingosine,

• hydrogenated lecithin,

• sodium carrageenan, and

• an extract of Porphyridium cruentum .

According to another particular embodiment, said cosmetic composition comprises, in a physiologically acceptable medium:

- calcium pantetheine sulfonate,

- hydroxypropyl cyclodextrin,

- phytosphingosine,

- hydrogenated lecithin,

- carrageenan sodium, and

- an extract of Porphyridium cruentum .

According to a particular embodiment, said cosmetic composition comprises, in a physiologically acceptable medium:

- calcium pantetheine sulfonate,

- phytosphingosine,

- hydrogenated lecithin and

- at least 1 ingredient, preferably at least 2 ingredients chosen from the group consisting of:

• hydroxypropyl cyclodextrin,

• sodium carrageenan, and

• an extract of Porphyridium cruentum .

Table 1 below illustrates different combinations of ingredients included in cosmetic compositions according to the invention:

Ingredients included in the cosmetic composition Calcium pantetheine sulfonate Phytosphingosine Hydrogenated lecithin Hydroxypropyl cyclodextrin Sodium carrageenan Extract of
Porphyridium cruentum Association 1 X X X X Association 2 X X X X Association 3 X X X X Association 4 X X X Association 5 X X X Association 6 X X X Association 7 X X X X X Association 8 X X X X X Association 9 X X X X X Association 10 X X X X Association 11 X X X X X X

According to a particular mode, the composition comprises one of the associations comprising at least calcium pantetheine sulfonate, phytosphingosine and hydrogenated lecithin, chosen from associations 1, 2, 3, 7, 8, 9 and 11, preferably the association 11.

Assets And combination of assets and composition s according to the invention

By “ active ” or “ cosmetic active ” we mean a compound or an ingredient which gives cosmetic compositions their properties. The ingredients used as active ingredients in the invention, in particular calcium pantetheine sulfonate advantageously in combination with hydroxypropyl cyclodextrin, and/or phytosphingosine, and/or hydrogenated lecithin, and/or sodium carrageenan, and/ or an extract of Porphyridium cruentum , are of interest for keratin materials, particularly for the skin. Indeed, and surprisingly, the Applicant was able to show that calcium pantetheine sulfonate and advantageously its association with other active ingredients have an antiviral and/or virucidal activity, which makes it possible to use these ingredients as cosmetic active ingredients for the hygienic cleaning and/or disinfection of keratin materials, in particular of the skin, and more particularly the skin of the face and/or hands.

By “ cleaning ” or “ hygienic disinfection ” is meant the reduction and/or elimination of the transient flora present on the keratin surfaces, particularly on the skin. By “ transient flora ” we mean pathogenic agents, and in particular bacteria and viruses and in particular viruses which are present on the skin following contact with droplets and/or objects contaminated by said virus. We will also speak in the application of an “ antiviral ” or “ virucidal ” effect, that is to say the fact of reducing and/or eliminating viruses.

By “ remanence ”, we mean the duration during which the composition applied to the skin will be active without renewal.

By “ virus ” we mean a submicroscopic infectious agent that replicates only within the living cells of an organism. In the context of the present invention, “ virus ” means a respiratory virus, such as coronaviruses, influenza viruses and rhinoviruses, which can persist on inanimate surfaces for a few days.

Influenza viruses belong to the “orthomyxovirus” family of RNA viruses which are made up of 3 groups (A, B and C), type A being the most virulent. Human-to-human transmission of the influenza virus occurs primarily through the air via respiratory droplets or aerosols, but can also occur through contact with contaminated surfaces. The cosmetic compositions according to the invention are therefore particularly useful for reducing and/or eliminating viral particles of the influenza virus present on keratin materials, in particular on the skin.

SARS-CoV-2 (COVID-19 virus), like MERS-CoV and SARS-CoV-1, belongs to the beta coronavirus family and is considered to have originated in bats and has spread to humans very recently. Like the influenza virus, human-to-human transmission of the SARS-CoV-2 virus occurs primarily through the air via respiratory droplets or aerosols, and through contact with contaminated surfaces. The cosmetic compositions according to the invention are therefore particularly useful for reducing and/or eliminating SARS-CoV-2 viral particles present on keratin materials, in particular on the skin.

Said assets may be, in certain embodiments, commercial products.

Calcium pantetheine sulfonate

By "calcium pantetheine sulfonate» means a derivative of vitamin B5, of formula PaSSO3Ca, generally obtained from botanical and/or plant extracts. THE " calcium pantetheine sulfonate » is particularly known in the field of cosmetics for its use as a depigmenting agent.

According to a preferred embodiment, the present invention uses calcium pantetheine sulfonate marketed by the company Sigma under the trade name 'CA D PANTETHEINE S SULFONATE', named INCI (international nomenclature of cosmetic ingredients) and abbreviation of International Nomenclature of Cosmetic Ingredients ): Calcium Pantetheine Sulfonate (and) Aqua. The raw material marketed under the name ‘CA D PANTETHEINE S SULFONATE’ comprises 70% by weight of calcium pantetheine sulfonate (active ingredient) in the raw material.

Hydroxypropyl cyclodextrin

By “ hydroxypropyl cyclodextrin ” is meant a cyclic polysaccharide, derived from cyclodextrin, which can be obtained from starch. Due to its cylindrical structure, hydroxypropyl cyclodextrin can form complexes with hydrophobic ingredients, carotenoids, retinoids and other perfume ingredients. “ Hydroxypropyl cyclodextrin ” is particularly known in the field of cosmetics for its use in anti-aging products, moisturizing facial lotions and deodorants.

According to a preferred embodiment, the present invention uses hydroxypropyl cyclodextrin marketed by the company Sigma under the trade name ‘KLEPTOSE HP’, INCI name: Hydroxypropyl Cyclodextrin. The raw material marketed under the name ‘KLEPTOSE HP’ comprises 100% by weight of hydroxypropyl cyclodextrin (active material) in the raw material.

Phytosphingosine

By “ phytosphingosine ” is meant a class of natural products containing a long aliphatic chain with a polar 2-amino-1,3-diol end. “ Sphingosines ” and “ phytosphingosines ” are natural constituents of the hydrolipidic film of the superficial layers of the skin. They contribute to good skin cohesion, and strengthen the skin barrier function. “ Phytosphingosines ” are known in the field of cosmetics for their use to treat dryness in mature skin, and/or to repair dry and damaged skin.

According to a preferred embodiment, the present invention uses phytosphingosine marketed by the company Evonik under the name 'LIPOSKIN II', INCI name: Hydrogenated Lecithin (and) Phytosphingosine (and) Cholesterol (and) C12-16 Alcohols (and) Palmitic Acid. The raw material marketed under the name ‘LIPOSKIN II’ includes 0.5% by weight of phytosphingosine (active ingredient) in the raw material.

According to another preferred embodiment, the present invention uses phytosphingosine marketed by the company Evonik under the name PHYTOSPHINGOSINE with INCI name: Phytosphingosine. The raw material marketed under the name ‘PHYTOSPHINGOSINE’ comprises 100% by weight of phytosphingosine (active ingredient) in the raw material.

Hydrogenated lecithin

By “ lecithin ” we mean a lipid from the phosphoglyceride class. By “ hydrogenated lecithin ” we mean lecithin to which hydrogen atoms have been added. Hydrogenated lecithin is known in the field of cosmetics for its use as a surfactant and/or emulsifier, in particular to help stabilize an oil and water mixture.

According to a preferred embodiment, the present invention uses hydrogenated lecithin marketed by the company Evonik under the name 'LIPOSKIN II' of INCI name: Hydrogenated Lecithin (and) Phytosphingosine (and) Cholesterol (and) C12-16 Alcohols (and) Palmitic Acid. The raw material marketed under the name ‘LIPOSKIN II’ comprises 19.85% by weight of hydrogenated lecithin (active material) in the raw material.

According to another preferred embodiment, the present invention uses hydrogenated lecithin marketed by the company Lucas Meyer Cosmetics under the name 'BIOPHILIC ^TM H' with INCI name: Hydrogenated Lecithin (and) C12-16 Alcohols (and) Palmitic Acid. The raw material marketed under the name 'BIOPHILIC ^TM H' includes 18% by weight of hydrogenated lecithin (active material) in the raw material.

Sodium carrageenan

By “ sodium carrageenan ” or “ sodium carrageenan ” we mean a marine biopolymer obtained from red marine algae. “ Sodium carrageenan ” is particularly known in the field of cosmetics for its use as a thickening and stabilizing agent for emulsions. It is also used as a film-forming and moisturizing agent.

According to a preferred embodiment, the present invention uses sodium carrageenan marketed by the company Codif under the trade name ‘HYDRANOV PA’, INCI name: Aqua (and) Phenethyl Alcohol (and) Sodium Carrageenan (and) Maris Sal. The raw material marketed under the name ‘HYDRANOV PA’ includes 0.6% by weight of sodium carrageenan (active material) in the raw material.

Porphyridium cruentum extract

By "extract of Porphyridium cruentum » means an isolated substance, obtained by extraction from microalgae of the speciesPorphyridium Cruentum, and which does not pre-exist in nature as such. TherePorphyridium Cruentumis a purplish-red microalgae, rich in nutrients, proteins, β-Phycoerythrin pigments and Exopolysaccharides. THE "extracts from Porphyridium cruentum »are particularly known in the field of cosmetics for their moisturizing and decongestant properties.

According to a preferred embodiment, the present invention uses an extract of Porphyridium cruentum marketed by the company Givaudan under the trade name 'HYDRINTENSE MB', INCI name: Maris Aqua (and) Propanediol (and) Porphyridium Cruentum Extract. The raw material marketed under the name 'HYDRINTENSE MB' includes 0.55% by weight of Porphyridium cruentum extract (active ingredient) in the raw material.

According to a particular embodiment, said cosmetic composition comprises, in a physiologically acceptable medium:

- calcium pantetheine sulfonate marketed by the company Sigma under the trade name ‘CA D PANTETHEINE S SULFONATE’, INCI name: Calcium Pantetheine Sulfonate (and) Aqua, and

- at least 2 ingredients chosen from the group consisting of:

• hydroxypropyl cyclodextrin marketed by the company Sigma under the trade name ‘KLEPTOSE HP’, INCI name: Hydroxypropyl Cyclodextrin,

• phytosphingosine marketed by the company Evonik under the name ‘PHYTOSPHINGOSINE’, INCI name: Phytosphingosine

• hydrogenated lecithin marketed by the company Lucas Meyer Cosmetics under the name 'BIOPHILIC ^TM H', INCI name: Hydrogenated Lecithin (and) C12-16 Alcohols (and) Palmitic Acid.

• sodium carrageenan marketed by the company Codif under the trade name ‘HYDRANOV PA’, INCI name: Aqua (and) Phenethyl Alcohol (and) Sodium Carrageenan (and) Maris Sal, and

• an extract of Porphyridium cruentum marketed by the company Givaudan under the trade name 'HYDRINTENSE MB', INCI name: Maris Aqua (and) Propanediol (and) Porphyridium Cruentum Extract.

According to an alternative embodiment, phytosphingosine and hydrogenated lecithin are both provided by the product marketed by the company Evonik under the name 'LIPOSKIN II', INCI name: Hydrogenated Lecithin (and) Phytosphingosine (and) Cholesterol (and) C12 -16 Alcohols (and) Palmitic Acid.

According to a particular embodiment, said cosmetic composition comprises, in a physiologically acceptable medium:

- calcium pantetheine sulfonate marketed by the company Sigma under the trade name ‘CA D PANTETHEINE S SULFONATE’, INCI name: Calcium Pantetheine Sulfonate (and) Aqua, and

- at least 3 ingredients chosen from the group consisting of:

• hydroxypropyl cyclodextrin marketed by the company Sigma under the trade name ‘KLEPTOSE HP’, INCI name: Hydroxypropyl Cyclodextrin,

• phytosphingosine marketed by the company Evonik under the name ‘PHYTOSPHINGOSINE’, INCI name: Phytosphingosine

• hydrogenated lecithin marketed by the company Lucas Meyer Cosmetics under the name 'BIOPHILIC ^TM H', INCI name: Hydrogenated Lecithin (and) C12-16 Alcohols (and) Palmitic Acid.

• sodium carrageenan marketed by the company Codif under the trade name ‘HYDRANOV PA’, INCI name: Aqua (and) Phenethyl Alcohol (and) Sodium Carrageenan (and) Maris Sal, and

• an extract of Porphyridium cruentum marketed by the company Givaudan under the trade name 'HYDRINTENSE MB', INCI name: Maris Aqua (and) Propanediol (and) Porphyridium Cruentum Extract.

According to an alternative embodiment, phytosphingosine and hydrogenated lecithin are both provided by the product marketed by the company Evonik under the name 'LIPOSKIN II', INCI name: Hydrogenated Lecithin (and) Phytosphingosine (and) Cholesterol (and) C12 -16 Alcohols (and) Palmitic Acid.

According to a particular embodiment, said cosmetic composition comprises, in a physiologically acceptable medium:

- calcium pantetheine sulfonate marketed by the company Sigma under the trade name ‘CA D PANTETHEINE S SULFONATE’, INCI name: Calcium Pantetheine Sulfonate (and) Aqua, and

- at least 4 ingredients chosen from the group consisting of:

• hydroxypropyl cyclodextrin marketed by the company Sigma under the trade name ‘KLEPTOSE HP’, INCI name: Hydroxypropyl Cyclodextrin,

• phytosphingosine marketed by the company Evonik under the name ‘PHYTOSPHINGOSINE’, INCI name: Phytosphingosine

• hydrogenated lecithin marketed by the company Lucas Meyer Cosmetics under the name 'BIOPHILIC ^TM H', INCI name: Hydrogenated Lecithin (and) C12-16 Alcohols (and) Palmitic Acid.

• sodium carrageenan marketed by the company Codif under the trade name ‘HYDRANOV PA’, INCI name: Aqua (and) Phenethyl Alcohol (and) Sodium Carrageenan (and) Maris Sal, and

• an extract of Porphyridium cruentum marketed by the company Givaudan under the trade name 'HYDRINTENSE MB', INCI name: Maris Aqua (and) Propanediol (and) Porphyridium Cruentum Extract.

According to an alternative embodiment, phytosphingosine and hydrogenated lecithin are both provided by the product marketed by the company Evonik under the name 'LIPOSKIN II', INCI name: Hydrogenated Lecithin (and) Phytosphingosine (and) Cholesterol (and) C12 -16 Alcohols (and) Palmitic Acid.

According to a particular embodiment, said cosmetic composition comprises, in a physiologically acceptable medium:

- calcium pantetheine sulfonate marketed by the company Sigma under the trade name ‘CA D PANTETHEINE S SULFONATE’, INCI name: Calcium Pantetheine Sulfonate (and) Aqua,

- phytosphingosine marketed by the company Evonik under the name ‘PHYTOSPHINGOSINE’ INCI name: Phytosphingosine,

- hydrogenated lecithin marketed by the company Lucas Meyer Cosmetics under the name 'BIOPHILIC ^TM H', INCI name: Hydrogenated Lecithin (and) C12-16 Alcohols (and) Palmitic Acid, and

- at least 1 ingredient chosen from the group consisting of:

• hydroxypropyl cyclodextrin marketed by the company Sigma under the trade name ‘KLEPTOSE HP’, INCI name: Hydroxypropyl Cyclodextrin,

• sodium carrageenan marketed by the company Codif under the trade name ‘HYDRANOV PA’, INCI name: Aqua (and) Phenethyl Alcohol (and) Sodium Carrageenan (and) Maris Sal, and

• an extract of Porphyridium cruentum marketed by the company Givaudan under the trade name 'HYDRINTENSE MB', INCI name: Maris Aqua (and) Propanediol (and) Porphyridium Cruentum Extract.

According to an alternative embodiment, phytosphingosine and hydrogenated lecithin are both provided by the product marketed by the company Evonik under the name 'LIPOSKIN II', INCI name: Hydrogenated Lecithin (and) Phytosphingosine (and) Cholesterol (and) C12 -16 Alcohols (and) Palmitic Acid.

According to a particular embodiment, said cosmetic composition comprises, in a physiologically acceptable medium:

- calcium pantetheine sulfonate marketed by the company Sigma under the trade name ‘CA D PANTETHEINE S SULFONATE’, INCI name: Calcium Pantetheine Sulfonate (and) Aqua,

- phytosphingosine marketed by the company Evonik under the name ‘PHYTOSPHINGOSINE’ INCI name: Phytosphingosine,

- hydrogenated lecithin marketed by the company Lucas Meyer Cosmetics under the name 'BIOPHILIC ^TM H', INCI name: Hydrogenated Lecithin (and) C12-16 Alcohols (and) Palmitic Acid, and

- at least 2 ingredients chosen from the group consisting of:

• hydroxypropyl cyclodextrin marketed by the company Sigma under the trade name ‘KLEPTOSE HP’, INCI name: Hydroxypropyl Cyclodextrin,

• sodium carrageenan marketed by the company Codif under the trade name ‘HYDRANOV PA’, INCI name: Aqua (and) Phenethyl Alcohol (and) Sodium Carrageenan (and) Maris Sal, and

• an extract of Porphyridium cruentum marketed by the company Givaudan under the trade name 'HYDRINTENSE MB', INCI name: Maris Aqua (and) Propanediol (and) Porphyridium Cruentum Extract.

According to an alternative embodiment, phytosphingosine and hydrogenated lecithin are both provided by the product marketed by the company Evonik under the name 'LIPOSKIN II', INCI name: Hydrogenated Lecithin (and) Phytosphingosine (and) Cholesterol (and) C12 -16 Alcohols (and) Palmitic Acid.

According to a particular embodiment, said cosmetic composition comprises, in a physiologically acceptable medium:

- calcium pantetheine sulfonate marketed by the company Sigma under the trade name ‘CA D PANTETHEINE S SULFONATE’, INCI name: CALCIUM PANTETHEINE SULFONATE (and) AQUA,

- hydroxypropyl cyclodextrin marketed by the company Sigma under the trade name ‘KLEPTOSE HP’, INCI name: Hydroxypropyl Cyclodextrin,

- phytosphingosine marketed by the company Evonik under the name ‘PHYTOSPHINGOSINE’, INCI name: Phytosphingosine,

- hydrogenated lecithin marketed by the company Lucas Meyer Cosmetics under the name 'BIOPHILIC ^TM H' INCI name: Hydrogenated Lecithin (and) C12-16 Alcohols (and) Palmitic Acid

- sodium carrageenan marketed by the company Codif under the trade name ‘HYDRANOV PA’, INCI name: Aqua (and) Phenethyl Alcohol (and) Sodium Carrageenan (and) Maris Sal, and

- an extract of Porphyridium cruentum marketed by the company Givaudan under the trade name 'HYDRINTENSE' MB, INCI name: Maris Aqua (and) Propanediol (and) Porphyridium Cruentum Extract.

According to an alternative embodiment, phytosphingosine and hydrogenated lecithin are both provided by the product marketed by the company Evonik under the name 'LIPOSKIN II', INCI name: Hydrogenated Lecithin (and) Phytosphingosine (and) Cholesterol (and) C12 -16 Alcohols (and) Palmitic Acid.

In their capacity as cosmetic active ingredients, calcium pantetheine sulfonate advantageously in association with hydroxypropyl cyclodextrin, and/or phytosphingosine, and/or hydrogenated lecithin, and/or sodium carrageenan, and/or an extract of Porphyridium cruentum are present in the cosmetic composition of the invention in an effective quantity to obtain the desired effect.

By “ effective quantity ” we designate the minimum quantity of cosmetic active ingredient(s) which is(are) necessary to obtain the beneficial effect according to the invention, namely a cleaning and/or softening effect. hygienic disinfection of keratin materials, particularly the skin.

Preferably, the calcium pantetheine sulfonate is present in the cosmetic composition according to the invention in a content ranging from 0.01% to 8% by weight relative to the total weight of the composition, preferably from 0.1% to 5% by weight. weight, and in particular from 0.4% to 1% by weight relative to the total weight of the composition. These percentages are expressed in weight of active ingredient relative to the total weight of the composition.

According to a particular method, calcium pantetheine sulfonate is provided by the commercial product ‘CA D PANTETHEINE S SULFONATE’. Preferably, the 'CA D PANTETHEINE S SULFONATE' is present in the cosmetic composition according to the invention in a content ranging from 0.01% to 8% by weight relative to the total weight of the composition, preferably 0.1 % to 5% by weight, and in particular from 0.4% to 1% by weight relative to the total weight of the composition. These percentages are expressed in weight of raw material (weight of product) relative to the total weight of the composition.

Preferably, the hydroxypropyl cyclodextrin is present in the cosmetic composition according to the invention in a content ranging from 0.01% to 5% by weight relative to the total weight of the composition, preferably from 0.05% to 2%. by weight, and in particular from 0.08% to 1.2% by weight relative to the total weight of the composition. These percentages are expressed in weight of active ingredient relative to the total weight of the composition.

According to a particular method, hydroxypropyl cyclodextrin is provided by the commercial product ‘KLEPTOSE HP’. Preferably, the 'KLEPTOSE HP' is present in the cosmetic composition according to the invention in a content ranging from 0.01% to 5% by weight relative to the total weight of the composition, preferably from 0.05% to 2 % by weight, and in particular from 0.08% to 1.2% by weight relative to the total weight of the composition. These percentages are expressed in weight of raw material (weight of product) relative to the total weight of the composition.

Preferably, the phytosphingosine is present in the cosmetic composition according to the invention in a content ranging from 0.001% to 5% by weight relative to the total weight of the composition, preferably from 0.01% to 1% by weight, and in particular from 0.02% to 0.05% by weight relative to the total weight of the composition. These percentages are expressed in weight of active ingredient relative to the total weight of the composition.

According to a particular method, phytosphingosine is provided by the commercial product ‘PHYTOSPHINGOSINE’ from the company Evonik. Preferably the 'PHYTOSPHINGOSINE' is present in the cosmetic composition according to the invention in a content ranging from 0.001% to 5% by weight relative to the total weight of the composition, preferably from 0.01% to 1% by weight, and in particular from 0.02% to 0.05% by weight relative to the total weight of the composition. These percentages are expressed in weight of active ingredient relative to the total weight of the composition.

According to a particular method, phytosphingosine is provided by the commercial product ‘LIPOSKIN II’. Preferably, the 'LIPOSKIN II' is present in the cosmetic composition according to the invention in a content ranging from 0.1% to 6% by weight relative to the total weight of the composition, preferably from 0.5% to 5 % by weight, and in particular from 1% to 4% by weight relative to the total weight of the composition. These percentages are expressed in weight of raw material (weight of product) relative to the total weight of the composition.

Preferably, the hydrogenated lecithin is present in the cosmetic composition according to the invention in a content ranging from 0.01% to 10% by weight relative to the total weight of the composition, preferably from 0.1% to 5% by weight. weight, and in particular from 0.2% to 1% by weight relative to the total weight of the composition. These percentages are expressed in weight of active material relative to the total weight of the composition.

According to a particular method, hydrogenated lecithin is provided by the commercial product 'BIOPHILIC ^TM H'. Preferably, the 'BIOPHILIC ^TM H' is present in the cosmetic composition used according to the invention in a content ranging from 0.1% to 10% by weight relative to the total weight of the composition, preferably 0.5% at 5% by weight, and in particular from 1% to 3% by weight relative to the total weight of the composition. These percentages are expressed in weight of raw material (weight of product) relative to the total weight of the composition.

According to a particular method, hydrogenated lecithin is provided by the commercial product ‘LIPOSKIN II’. Preferably, the 'LIPOSKIN II' is present in the cosmetic composition according to the invention in a content ranging from 0.1% to 6% by weight relative to the total weight of the composition, preferably from 0.5% to 5 % by weight, and in particular from 1% to 4% by weight relative to the total weight of the composition. These percentages are expressed in weight of raw material (weight of product) relative to the total weight of the composition.

Preferably, sodium carrageenan is present in the cosmetic composition according to the invention in a content ranging from 0.001% to 5% by weight relative to the total weight of the composition, preferably from 0.0015% to 1% by weight, and in particular from 0.01% to 0.5% by weight relative to the total weight of the composition. These percentages are expressed in weight of active ingredient relative to the total weight of the composition.

According to a particular method, sodium carrageenan is provided by the commercial product ‘HYDRANOV PA’. Preferably, the 'HYDRANOV PA' is present in the cosmetic composition according to the invention in a content ranging from 0.1% to 5% by weight relative to the total weight of the composition, preferably from 0.5% to 4 % by weight, and in particular from 1% to 3% by weight relative to the total weight of the composition. These percentages are expressed in weight of raw material (weight of product) relative to the total weight of the composition.

Preferably, the Porphyridium cruentum extract is present in the cosmetic composition according to the invention in a content ranging from 0.001% to 5% by weight relative to the total weight of the composition, preferably from 0.0015% to 3%. by weight, and in particular from 0.01% to 1% by weight relative to the total weight of the composition. These percentages are expressed in weight of active ingredient relative to the total weight of the composition.

According to a particular method, the extract of Porphyridium cruentum is provided by the commercial product 'HYDRINTENSE MB'. Preferably, the 'HYDRINTENSE MB' is present in the cosmetic composition according to the invention in a content ranging from 0.1% to 10% by weight relative to the total weight of the composition, preferably from 1% to 8% by weight. weight, and in particular from 3% to 6% by weight relative to the total weight of the composition. These percentages are expressed in weight of raw material (weight of product) relative to the total weight of the composition.

According to a particular embodiment, said cosmetic composition comprises:

- calcium pantetheine sulfonate in a content ranging from 0.01% to 8% by weight relative to the total weight of the composition, and

- at least 2 ingredients chosen from the group consisting of:

• hydroxypropyl cyclodextrin in a content ranging from 0.01% to 5% by weight relative to the total weight of the composition,

• phytosphingosine in a content ranging from 0.001% to 5% by weight relative to the total weight of the composition,

• hydrogenated lecithin in a content ranging from 0.01% to 10% by weight relative to the total weight of the composition,

• sodium carrageenan in a content ranging from 0.001% to 5 by weight relative to the total weight of the composition, and

• an extract of P orphyridium cruentum in a content ranging from 0.001% to 5% by weight relative to the total weight of the composition .

According to a particular embodiment, said cosmetic composition comprises:

- calcium pantetheine sulfonate in a content ranging from 0.01% to 8% by weight relative to the total weight of the composition, and

- at least 3 ingredients chosen from the group consisting of:

• hydroxypropyl cyclodextrin in a content ranging from 0.01% to 5% by weight relative to the total weight of the composition,

• phytosphingosine in a content ranging from 0.001% to 5% by weight relative to the total weight of the composition,

• hydrogenated lecithin in a content ranging from 0.01% to 10% by weight relative to the total weight of the composition,

• sodium carrageenan in a content ranging from 0.001% to 5 by weight relative to the total weight of the composition, and

• an extract of Porphyridium cruentum in a content ranging from 0.001% to 5% by weight relative to the total weight of the composition .

According to a particular embodiment, said cosmetic composition comprises:

- calcium pantetheine sulfonate in a content ranging from 0.01% to 8% by weight relative to the total weight of the composition, and

- at least 4 ingredients chosen from the group consisting of:

• hydroxypropyl cyclodextrin in a content ranging from 0.01% to 5% by weight relative to the total weight of the composition,

• phytosphingosine in a content ranging from 0.001% to 5% by weight relative to the total weight of the composition,

• hydrogenated lecithin in a content ranging from 0.01% to 10% by weight relative to the total weight of the composition,

• sodium carrageenan in a content ranging from 0.001% to 5 by weight relative to the total weight of the composition, and

• an extract of Porphyridium cruentum in a content ranging from 0.001% to 5% by weight relative to the total weight of the composition .

According to a particular embodiment, said cosmetic composition comprises:

- calcium pantetheine sulfonate in a content ranging from 0.01% to 8% by weight relative to the total weight of the composition,

- phytosphingosine in a content ranging from 0.001% to 5% by weight relative to the total weight of the composition,

- hydrogenated lecithin in a content ranging from 0.01% to 10% by weight relative to the total weight of the composition, and

- at least 1 ingredient chosen from the group consisting of:

• hydroxypropyl cyclodextrin in a content ranging from 0.01% to 5% by weight relative to the total weight of the composition,

• sodium carrageenan in a content ranging from 0.001% to 5 by weight relative to the total weight of the composition, and

• an extract of Porphyridium cruentum in a content ranging from 0.001% to 5% by weight relative to the total weight of the composition .

According to a particular embodiment, said cosmetic composition comprises:

- calcium pantetheine sulfonate in a content ranging from 0.01% to 8% by weight relative to the total weight of the composition,

- phytosphingosine in a content ranging from 0.001% to 5% by weight relative to the total weight of the composition,

- hydrogenated lecithin in a content ranging from 0.01% to 10% by weight relative to the total weight of the composition, and

- at least 2 ingredients chosen from the group consisting of:

• hydroxypropyl cyclodextrin in a content ranging from 0.01% to 5% by weight relative to the total weight of the composition,

• sodium carrageenan in a content ranging from 0.001% to 5 by weight relative to the total weight of the composition, and

• an extract of Porphyridium cruentum in a content ranging from 0.001% to 5% by weight relative to the total weight of the composition .

According to a particular embodiment, said cosmetic composition comprises:

- calcium pantetheine sulfonate in a content ranging from 0.01% to 8% by weight relative to the total weight of the composition,

- phytosphingosine in a content ranging from 0.001% to 5% by weight relative to the total weight of the composition,

- hydrogenated lecithin in a content ranging from 0.01% to 10% by weight relative to the total weight of the composition,

- hydroxypropyl cyclodextrin in a content ranging from 0.01% to 5% by weight relative to the total weight of the composition,

- sodium carrageenan in a content ranging from 0.001% to 5 by weight relative to the total weight of the composition, and

- an extract of Porphyridium cruentum in a content ranging from 0.001% to 5% by weight relative to the total weight of the composition .

Galenics

By “ cosmetic composition ” is meant any composition for cosmetic purposes, which can be brought into contact with the superficial parts of the human body and more particularly with keratin materials, in particular human skin.

The composition of the invention is a non-rinsed care composition, as opposed to a rinse-off cleaning composition.

By “ physiologically acceptable medium ” is meant any excipient suitable for topical use, in contact with keratin materials, without risk of toxicity, incompatibility, instability and/or allergic response. The physiologically acceptable medium generally represents 1 to 99% by weight, relative to the total weight of said composition.

The cosmetic composition according to the invention generally comprises calcium pantetheine sulfonate advantageously in association with hydroxypropyl cyclodextrin, and/or phytosphingosine, and/or hydrogenated lecithin, and/or sodium carrageenan, and/or an extract of Porphyridium cruentum , the physiologically acceptable medium, and in addition one or more acceptable cosmetic excipients among those known to those skilled in the art with a view to obtaining a composition for topical application for example in the form of a cream, oil-in-emulsion water, or water-in-oil or multiple emulsion, solution, suspension, gel, milk, lotion, serum, balm, stick, or even powder.

According to a particular embodiment, the cosmetic composition according to the invention is in the form of a cream, oil-in-water emulsion, or water-in-oil or multiple emulsion, solution, oil, suspension, gel, milk, lotion, or serum.

In a preferred embodiment, said composition according to the invention is in the form of a cream or a serum.

The cosmetic composition according to the invention can be presented in any galenic form suitable for topical application to the skin and in particular to the skin of the face and/or hands, comprising calcium pantetheine sulfonate advantageously in association with hydroxypropyl cyclodextrin, and /or phytosphingosine, and/or hydrogenated lecithin, and/or sodium carrageenan, and/or an extract of Porphyridium cruentum , and at least one cosmetic adjuvant chosen from antioxidants, perfumes, vitamins, thickening agents, emollient agents, moisturizing agents, anti-aging agents, soothing agents, anti-pollution agents, fillers, pearls and mixtures thereof.

Also, according to a particular mode, the cosmetic composition according to the invention may further comprise at least one cosmetic adjuvant chosen from the group consisting of: antioxidant agents, emollient agents, moisturizing agents, anti-aging agents, and their mixtures.

Depending on the nature of the composition, one or more cosmetically acceptable excipients will be selected from emulsifiers, polymers, surfactants, rheology agents, electrolytes, pH adjusters, anti-oxidant agents, preservatives, dyes. , and their mixtures.

As a particular example, the cosmetic composition according to the invention may comprise gelling agents, antioxidants, preservatives and mixtures thereof.

The cosmetic composition according to the invention may also comprise a fatty phase (solid fatty substances) or oily phase.

By “ oil phase ” is meant an oil or a mixture of oils which may or may not be miscible with each other. By “oil” is meant, within the meaning of the invention, a fatty substance, not soluble in water, liquid at 25°C and atmospheric pressure. These oils can be vegetable, mineral or synthetic.

An oily phase according to the invention may comprise hydrocarbon oils, preferably of vegetable origin, silicone oils, and mixtures thereof, preferably hydrocarbon oils and in particular of vegetable origin.

The content of fatty or oily phase in the cosmetic composition of the invention will generally range from 0.2% to 45%, preferably from 0.5% to 30%, and more preferably from 2% to 25% by weight per relative to the total weight of said composition.

Cosmetic process, cosmetic use and other uses

Thus, the present invention relates to the use of calcium pantetheine sulfonate, or of a cosmetic composition comprising it, for the hygienic cleaning and/or disinfection of keratin materials, in particular of the skin.

The present invention also relates to the use of a combination of ingredients as defined above, in particular the combination of:

- calcium pantetheine sulfonate, and

- at least 2 ingredients chosen from the group consisting of:

• hydroxypropyl cyclodextrin,

• phytosphingosine,

• hydrogenated lecithin,

• sodium carrageenan, and

• an extract of Porphyridium cruentum ,

for the hygienic cleaning and/or disinfection of keratin materials, in particular the skin.

According to a particular mode, the invention relates to the use of a combination of ingredients as defined above, in particular the combination of:

- calcium pantetheine sulfonate, and

- at least 3 ingredients chosen from the group consisting of:

• hydroxypropyl cyclodextrin,

• phytosphingosine,

• hydrogenated lecithin,

• sodium carrageenan, and

• an extract of Porphyridium cruentum ,

for the hygienic cleaning and/or disinfection of keratin materials, in particular the skin.

According to a particular mode, the invention relates to the use of a combination of ingredients as defined above, in particular the combination of:

- calcium pantetheine sulfonate, and

- at least 4 ingredients chosen from the group consisting of:

• hydroxypropyl cyclodextrin,

• phytosphingosine,

• hydrogenated lecithin,

• sodium carrageenan, and

• an extract of Porphyridium cruentum ,

for the hygienic cleaning and/or disinfection of keratin materials, in particular the skin.

According to a particular mode, the invention relates to the use of a combination of ingredients as defined above, in particular the combination of:

- calcium pantetheine sulfonate,

- phytosphingosine,

- hydrogenated lecithin, and

- at least 1 ingredient chosen from the group consisting of:

• hydroxypropyl cyclodextrin,

• sodium carrageenan, and

• an extract of Porphyridium cruentum ,

for the hygienic cleaning and/or disinfection of keratin materials, in particular the skin.

According to a particular mode, the invention relates to the use of a combination of ingredients as defined above, in particular the combination of:

- calcium pantetheine sulfonate,

- phytosphingosine,

- hydrogenated lecithin, and

- at least 2 ingredients chosen from the group consisting of:

• hydroxypropyl cyclodextrin,

• sodium carrageenan, and

• an extract of Porphyridium cruentum ,

for the hygienic cleaning and/or disinfection of keratin materials, in particular the skin.

According to a particular mode, the invention relates to the use of an association:

- calcium pantetheine sulfonate,

- hydroxypropyl cyclodextrin,

- phytosphingosine,

- hydrogenated lecithin,

- carrageenan sodium, and

- an extract of Porphyridium cruentum ,

for the hygienic cleaning and/or disinfection of keratin materials, in particular the skin.

By “ keratin materials ” according to the invention is meant the skin and/or its integuments, and more particularly human skin. In particular, this will concern the skin of the face and/or hands.

According to a preferred embodiment, the present invention relates to the use of a cosmetic composition as defined above, for the hygienic cleaning and/or disinfection of the skin and in particular the skin of the face and/or hands.

According to a preferred embodiment, the present invention relates to the use of a cosmetic composition as defined above, for the hygienic cleaning and/or disinfection of hands.

The cosmetic processes and cosmetic uses according to the invention are intended for application on healthy keratin materials, preferably skin, in particular the skin of the face and/or hands, of healthy subjects.

By “ healthy keratin materials ” (“ healthy ” subjects) is meant that the keratin materials do not present disorders or disorders that would result from a pathological state (“ unhealthy ” subjects, affected by a pathology). In the context of the present invention, we will speak indifferently of “ healthy skin ” or “ skin ”.

According to a particular mode, the composition of the invention can be used by any person with fragile skin or dry skin or likely to have irritated skin in contact with conventional hydroalcoholic solutions.

According to a particular mode, the composition of the invention can be used by any person having a need to clean and/or disinfect their hands very frequently, and therefore at risk of having weakened and/or dry skin and/or or irritated by regular contact with conventional solutions, particularly hydroalcoholic solutions.

According to a particular mode, the composition of the invention can be used by staff in hospitals, in maternity wards, in nursing homes or any person in contact with people at risk (e.g. babies, elderly people, immuno- depressed…).

Another object of the invention relates to a cosmetic process for cleansing and/or purifying keratin materials, in particular of the skin, in particular the skin of the hands and/or face, comprising the application to said keratin materials, of at least one layer of cosmetic composition as defined above.

Another subject of the invention relates to calcium pantetheine sulfonate for its use as an antiviral and/or virucidal agent for the hygiene of keratin materials, in particular facial and/or hand hygiene.

The present invention also relates to the combination of ingredients as defined above, in particular the combination of:

- calcium pantetheine sulfonate, and

- at least 2 ingredients chosen from the group consisting of:

• hydroxypropyl cyclodextrin,

• phytosphingosine,

• hydrogenated lecithin,

• sodium carrageenan, and

• an extract of Porphyridium cruentum ,

for its use as an active antiviral and/or virucidal association for the hygiene of keratin materials, in particular facial and/or hand hygiene.

According to a particular mode, the invention relates to the combination of ingredients as defined above, in particular the association of:

- calcium pantetheine sulfonate, and

- at least 3 ingredients chosen from the group consisting of:

• hydroxypropyl cyclodextrin,

• phytosphingosine,

• hydrogenated lecithin,

• sodium carrageenan, and

• an extract of Porphyridium cruentum ,

for its use as an active antiviral and/or virucidal association for the hygiene of keratin materials, in particular facial and/or hand hygiene.

According to a particular mode, the invention relates to the combination of ingredients as defined above, in particular the association of:

- calcium pantetheine sulfonate, and

- at least 4 ingredients chosen from the group consisting of:

• hydroxypropyl cyclodextrin,

• phytosphingosine,

• hydrogenated lecithin,

• sodium carrageenan, and

• an extract of Porphyridium cruentum ,

for its use as an active antiviral and/or virucidal association for the hygiene of keratin materials, in particular facial and/or hand hygiene.

According to a particular mode, the invention relates to the combination of ingredients as defined above, in particular the association of:

- calcium pantetheine sulfonate,

- phytosphingosine,

- hydrogenated lecithin and

- at least 1 ingredient chosen from the group consisting of:

• hydroxypropyl cyclodextrin,

• sodium carrageenan, and

• an extract of Porphyridium cruentum ,

for its use as an active antiviral and/or virucidal association for the hygiene of keratin materials, in particular facial and/or hand hygiene.

According to a particular mode, the invention relates to the combination of ingredients as defined above, in particular the association of:

- calcium pantetheine sulfonate,

- phytosphingosine

- hydrogenated lecithin, and

- at least 2 ingredients chosen from the group consisting of:

• hydroxypropyl cyclodextrin,

• sodium carrageenan, and

• an extract of Porphyridium cruentum ,

for its use as an active antiviral and/or virucidal association for the hygiene of keratin materials, in particular facial and/or hand hygiene.

According to a particular mode, the invention relates to the association:

- calcium pantetheine sulfonate,

- hydroxypropyl cyclodextrin,

- phytosphingosine,

- hydrogenated lecithin,

- sodium carrageenan, and

- an extract of Porphyridium cruentum ,

for its use as an active antiviral and/or virucidal association for the hygiene of keratin materials, in particular facial and/or hand hygiene.

The present invention also relates to a method of disinfection and/or cleaning of keratin materials, in particular of the skin of the face and/or hands, comprising the steps consisting of:

- provide a composition as defined above, and

- apply the composition by friction to the surface of the keratin material to be disinfected and/or cleaned.

The present invention will now be illustrated in the following non-limiting examples. Unless otherwise indicated, the % are expressed as % by weight relative to the total weight of said composition.

Examples Example 1: Valued Assets

The assets valued in the examples are:

- Calcium pantetheine sulfonate, INCI name: Calcium Pantetheine Sulfonate, marketed by the company Sigma under the trade name ‘CA D PANTETHEINE S SULFONATE’ INCI name: Calcium Pantetheine Sulfonate (and) Aqua. The raw material marketed under the name CA D PANTETHEINE S SULFONATE comprises 70% by weight of calcium pantetheine sulfonate (active ingredient) in the raw material.

- Hydroxypropyl cyclodextrin, INCI name: Hydroxypropyl Cyclodextrin, marketed by the company Sigma under the trade name ‘KLEPTOSE HP’, INCI name: Hydroxypropyl Cyclodextrin. The raw material marketed under the name ‘KLEPTOSE HP’ comprises 100% by weight of hydroxypropyl cyclodextrin (active material) in the raw material.

- Extract of P orphyridium cruentum, INCI name: Porphyridium Cruentum Extract, marketed by the company Givaudan under the trade name 'HYDRINTENSE MB', INCI name: Maris Aqua (and) Propanediol (and) Porphyridium Cruentum Extract. The raw material marketed under the name 'HYDRINTENSE MB' includes 0.55% by weight of Porphyridium c ruentum extract (active material) in the raw material.

- Sodium carrageenan, INCI name: Sodium Carrageenan, marketed by the company Codif under the trade name ‘HYDRANOV PA’, INCI name: Aqua (and) Phenethyl Alcohol (and) Sodium Carrageenan (and) Maris Sal. The raw material marketed under the name ‘HYDRANOV PA’ includes 0.6% by weight of sodium carrageenan (active material) in the raw material.

- Phytosphingosine, INCI name: Phytosphingosine and hydrogenated lecithin, INCI name: Hydrogenated Lecithin, marketed by the company Evonik under the trade name 'LIPOSKIN II', INCI name: Hydrogenated Lecithin (and) Phytosphingosine (and) Cholesterol (and) C12-16 Alcohols (and) Palmitic Acid. The raw material marketed under the name ‘LIPOSKIN II’ comprises 0.5% by weight of phytosphingosine (active material) and 19.85% by weight of hydrogenated lecithin (active material) in the raw material.

Example 2: Experimental design

This study aims to explore the protective effect of different active ingredients, or combinations of active ingredients, against the risks of viral infections mediated by contact with the hands, in particular by the influenza virus and/or the COVID-19 virus. .

For this purpose, modified lentiviral vectors were used. These lentiviral vectors have been modified in such a way that the lentiviral particles produced expose on their surface antigens specific to a viral strain of interest, namely the HANA surface protein in the case of the influenza virus (these particles are designated “HA-VPs”) and the surface protein SPIKE in the case of the SARS-CoV-2 virus (these particles are designated “Spike-VPs”). We will talk about pseudotyped particles. The lentiviral particles produced further express a fluorescent reporter gene, which facilitates the measurement of infection efficiencies.

Two viral batches of particles pseudotyped “HA-VPs” or “Spike-VPs” were generated, purified and titrated using permissive human HEK293T cells (see materials and methods below).

Example 3 : Study of the virucidal effect of the c alcium pantetheine sulfonate

3.1. Material and method

3.1.1. Preparation of vectors lentivirals

The lentiviral particles were produced from HEK293T cells (4.10 ⁶ cells per 10 cm diameter culture dish). The day following culturing, the cells were transfected using the JetOptimus kit (Polyplus).

For the preparation of “HA-VPs” lentiviral particles, the cells were transfected with 4 μg of PAX-2 plasmid (lentiviral envelope plasmid, Addgene), 0.3 μg of pCI-M2 plasmid (M2 protein of the virus influenza, Addgene), 1 µg of pNAHA (influenza virus HA protein, Addgene), and 3.7 µg of RFP lentivector (Addgene).

For the preparation of “Spike-VPs” lentiviral particles, the lentiviral particles were produced using 1 µg of HDM-SRAS2-Spike-del21-D614G plasmid (viral envelope plasmid, Addgene) and 3.7 µg of SWINGY (construction “reporter” carrying the YFP gene under the control of a CMV early promoter, Addgene).

The supernatants containing the lentiviral particles were collected 48 hours after transfection, clarified by 5 minutes of centrifugation at 500 g before being filtered through a 0.45 μm filter. The particles were then ultracentrifuged at 20,000 rpm (rotation per minute) in an SW41 rotor (Beckman) at 7°C for 80 minutes. The sedimented lentiviral particles were resuspended in cold PBS to obtain a 100x concentration and frozen at -80°C.

3.1.2. Vector titling lentivirals

To calculate the titer of the “HA-VP” and “Spike-VP” preparations, 2.10 ⁵ HEK293T cells were transduced with serial dilutions of the lentiviral preparation (lentiviral particles). A FACS analysis of the fluorescence of the cells, 72 hours after transduction, made it possible to measure the percentage of transduced cells and to calculate the titers in number of transduction units per ml (TU/ml). In the test described below, a concentration of approximately 10 ⁶ particles per ml was used.

3.1.3 Evaluation of the virucidal effect in cell culture

HEK293T target cells were seeded in a 96-well plate, at a concentration of 2.10 ⁵ cells per well, and cultured under standard culture conditions (DMEM medium + 10% FBS (fetal calf serum) at 37°C, 5 % CO2).

After 24 hours of culture, the cells were incubated for 3 hours in the presence of the active ingredients: Calcium pantetheine sulfonate (raw material sold under the name CA D PANTETHEINE S SULFONATE) or Hydroxypropyl cyclodextrin (raw material sold under the name KLEPTOSE HP) as described to example 1 above; or without active ingredient: PBS control condition (phosphate buffer saline).

These active ingredients were diluted to a concentration of 0.01% (% by weight of raw material) in the culture medium (DMEM + 10% FCS).

After 3 hours, 40µL of the inoculum of HA particles “HA-VP” were added to the cells, then an additional active ingredient was added to maintain the exact concentrations.

After 48 hours of culture, the target cells were analyzed by cytometry and the infection efficiencies measured (mean fluorescence). The results are presented in the (in % inhibition calculated with regard to the average of infections carried out without active ingredient (PBS control)).

3.2. Result s

The results illustrated in show that treatment with calcium pantetheine sulfonate allows a significant reduction in the viral titer of “HA-VP” particles (-67%; p<0.05). Surprisingly, the observed effect is greater than with hydroxypropyl cyclodextrin (-53%; p<0.05), known for its virucidal effect (László Jicsinszky et al., 2021).

Example 4 : Study of the virucidal effect of combination s of assets according to the invention

4.1. Material and methods

4.1.1. Asset preparation

For the purposes of this example, the active ingredients described in Example 1 were present in a basic cosmetic formulation, also called a placebo formula (see composition in Table 2).

Ingredients of the placebo formula Content (%) Cosmetic purified water QSP 100 VEGETABLE SQUALANE 6 TRI CAPRAT/CAPRYLAT GLYCEROL 6 VEGETABLE GLYCEROL 3 STEARYL ALCOHOL 1 CHLORPHENESIN 0.27 SODIUM HYDROXIDE 0.025

The concentrations used are as follows:

- calcium pantetheine sulfonate was used at a concentration of 0.49% by weight of active ingredient, relative to the total weight of the composition,

- hydroxypropyl cyclodextrin was used at a concentration of 0.10% by weight of active ingredient, relative to the total weight of the composition,

- the extract of Porphyridium cruentum was used at a concentration of 0.027% by weight of active ingredient, relative to the total weight of the composition,

- carrageenan sodium was used at a concentration of 0.012% by weight of active ingredient, relative to the total weight of the composition,

- phytosphingosine was used at a concentration of 0.01% by weight of active ingredient, relative to the total weight of the composition,

- hydrogenated lecithin was used at a concentration of 0.4% by weight of active ingredient, relative to the total weight of the composition.

The formulas evaluated are as follows:

Formula number Composition of the formula s evaluated s P1 Placebo + formula
Calcium pantetheine sulfonate + Hydroxypropyl cyclodextrin + Porphyridium cruentum extract + Sodium carrageenan P2 =
P1 + Phytosphingosine + Hydrogenated lecithin Placebo formula
Calcium pantetheine sulfonate + Hydroxypropyl cyclodextrin + Porphyridium cruentum extract + Sodium carrageenan
+ Phytosphingosine + Hydrogenated lecithin P3 Placebo formula P4 Placebo formula
+ Phytosphingosine + Hydrogenated lecithin P5 PBS P6 Cooper Ethanol brand hydroalcoholic gel (CAS n°64-17-5): 57.6% (m/m) Propane-2-ol (CAS n°67-63-0): 19.00% (m/ m).

4.1.2. Remanence tests on human skin explants

This test makes it possible to evaluate the survival of viral particles in the skin, and to determine whether the different active ingredients used in combination according to the invention have an impact on the survival of these viral particles (as prepared in Example 3). ).

To do this, experiments were carried out on skin biopsies prepared from surgical residues from healthy adult volunteers (Nativeskin, Genoskin kits). The skin explants were cultured on a 12-well plate in a nutrient medium. In this system, the surface of the skin is exposed and equipped with a silicone ring allowing the deposition, in its center, of a droplet of liquid which is thus maintained on the surface of the skin until evaporation.

In order to evaluate the antiviral or virucidal effect of the active ingredients evaluated, the explants were first cultured at 37°C for 48 hours, then the different preparations, that is to say the formulas P1 to P6 (see table 3) were applied by brushing onto the explants using a polypropylene micro-pusher (Sigma). For each condition, 2 mg of cream per cm2 was applied until completely absorbed.

After application, the skin explants were left for 3 hours at room temperature, then 50 μl of a viral inoculum, containing pseudo-infectious particles (non-replicative “Spike-VP” (at approximately 10 ⁶ particles per ml), were deposited in the center of the silicone ring After 30 min at room temperature, the “leaving” inoculum was then taken for immediate titration.

4.1.3. Titration following the persistence test (outgoing inoculum)

To titrate the remaining lentiviral particles at the end of the carryover assay, HEK293T cells genetically modified to express the Sars-COV-2 receptor (ACE2 as well as the TMPRSS2 protease) were prepared by transfecting 10 ⁵ HEK293T cells by 0.75 µg of ACE2 (angiotensin-converting enzyme 2, Addgene) and 0.25 µg of TMPRSS2 (transmembrane serine protease 2, Addgene) in a 12-well plate.

The following day, approximately 2 × 10 ⁵ of these cells were transduced by the outgoing inoculum. Transduction was carried out in 300 μl of DMEM supplemented with 10% FCS (Fetal Calf Serum) to which 20 μl of the outgoing inoculum was added. After 3 hours, 500 μl of fresh medium was added for cell growth and optimal expression of fluorescent transgenes. The cells were thus cultured for 72 hours, at 37°C.

The titration was then carried out by FACS. The percentage of cells expressing YFP reflects efficient transduction by lentiviral “Spike-VP” particles, i.e. the rate of residual infection by the COVID-19 virus in the outgoing inoculum.

4.1.4. Remarks

These experiments were carried out in duplicate. The two experiments were carried out three days apart, the second reusing the explants used for the first (dedicating the same explants to the same formulas). Cleaning of the explants was carried out between the two manipulations. Within each experiment, the formulas were tested in duplicate, the results given for each experiment representing the average of the two values.

Furthermore, the inoculums were used at non-saturating titrations, i.e. not all cells were infected in the control condition.

4.2. Results

The results (shown in ) are expressed as % inhibition of the infection rate compared to the PBS control (=condition P5, representing the 0% inhibition level).

We note that treatments with formula P3 (placebo formula alone) or with formula P1 (placebo formula + 4 active ingredients (see table 3)) produce weak inhibition of viral infection (respectively -1% and -5%) . Treatment with formula P4 (placebo formula + phytosphingosine + hydrogenated lecithin) allows 27% inhibition of the infection.

Surprisingly, we note that treatment with formula P2 (placebo formula + 6 active ingredients = formula P1 + phytosphingosine + hydrogenated lecithin) makes it possible to obtain strong inhibition of infection (-44%, p<0.05) ). The combination of the 6 active ingredients therefore seems to produce a synergistic antiviral or virucidal effect. In addition, this inhibition is comparable to what is obtained with a hydroalcoholic gel (condition P6, -47%). This combination is therefore particularly advantageous because it is as effective from the point of view of its antiviral effectiveness as a hydroalcoholic gel, but is much gentler and beneficial for the skin than a hydroalcoholic gel (sticky appearance, potentially irritating, drying, etc.) .

Example 5: Study of maintaining the effect antiviral in time (remanence of the effect)

5.1. Material and methods

The inoculum is produced as described previously. In this study, three independent tests were carried out on two series of Genoskin skin explants (from two different donors).

• une crème correspondant à la formule placébo additionnée des 6 actifs (correspondant à la formule P2 du tableau 3), ou
• un gel hydroalcoolique de marque Cooper Ethanol (CAS n°64-17-5) : 57,6% (m/m) Propane-2-ol (CAS n°67-63-0) : 19,00% (m/m).

The skin explants were treated by painting with:

• a cream corresponding to the placebo formula plus the 6 active ingredients (corresponding to formula P2 in table 3), or
• a Cooper Ethanol brand hydroalcoholic gel (CAS n°64-17-5): 57.6% (m/m) Propane-2-ol (CAS n°67-63-0): 19.00% (m/m) m).

The skin explants in the GENOSKIN basket (Nativeskin Access) were treated with the inoculum at room temperature (22 to 24°C) for a period of 30 minutes, then the inoculums were recovered with a pipette.

The viral particles were then titrated by cytometric analysis of the target cells, by measuring YFP (yellow fluorescent marker, see example 3.1.1. above), corresponding to “spike-VP” particles.

A second treatment with the inoculum was carried out at t = 80 minutes.

Half of the viral particles were recovered after 30 minutes (t=110 minutes), and the other half after 100 minutes (t=3 hours or t=180 minutes), of incubation at room temperature.

The viral particles collected at t=110 minutes and t=180 minutes were also titrated by cytometric analysis.

5.2. R results

At t=30 min, the placebo cream containing the 6 active ingredients used according to the invention is systematically active in all tests to inhibit infection by “spike-VP” particles (100% inhibition, result equivalent to hydroalcoholic gel control). Surprisingly, we see that at time t=110 minutes, the cream containing the 6 active ingredients still inhibits the infection by 60% while the hydroalcoholic gel is no longer active. The result observed for the cream containing the 6 active ingredients at t=180 minutes is identical, with 60% inhibition of infection (see ).

The cosmetic composition according to the invention is therefore particularly advantageous since it has an antiviral action prolonged over time (remanence of the effect), at least up to 3 hours, unlike the hydroalcoholic gel which is no longer effective quickly after its application.

Example 6: Cosmetic compositions according to the invention

The compositions are prepared according to the classic methods used in the cosmetic field:

- Oily phase :

The ingredients of the fatty phase are heated to 65°C with stirring (~ 400 rpm) until completely melted.

- Aqueous phase :

The ingredients of the aqueous phase are heated to 60°C with deflocculating stirring until complete solubilization.

Finally, the fatty phase is incorporated into the aqueous phase, at room temperature, with stirring (~ 400 rpm), until an emulsion is obtained.

The % contents are expressed in weight of raw material relative to the total weight of the composition.

Ingredients Content (%) Cosmetic purified water QSP 100 VEGETABLE SQUALANE 6 TRI CAPRAT/CAPRYLAT GLYCEROL 6 VEGETABLE GLYCEROL 3 ‘CA D PANTETHEINE S SULFONATE’ from the company Sigma and INCI name: Calcium Pantetheine Sulfonate (And) Aqua (70% by weight of calcium pantetheine sulfonate (active ingredient in the commercial raw material)). 0.7% (i.e. 0.49% in active ingredient) STEARYL ALCOHOL 1 CHLORPHENESIN 0.27 SODIUM HYDROXIDE 0.025

Applied to the skin of the hands and/or face by friction and without rinsing, this cream provides an antiviral effect without drying the skin.

Ingredients Content (%) Cosmetic purified water QSP 100 VEGETABLE SQUALANE 6 TRI CAPRAT/CAPRYLAT GLYCEROL 6 VEGETABLE GLYCEROL 3 ‘CA D PANTETHEINE S SULFONATE’ from the company Sigma and INCI name: Calcium Pantetheine Sulfonate (and) Aqua (70% by weight of calcium pantetheine sulfonate (active ingredient in the commercial raw material)). 0.7% (i.e. 0.49% in active ingredient) ‘PHYTOSPHINGOSINE’ from the company Evonik and INCI name: Phytosphingosine (100% by weight of phytosphingosine (active ingredient in the commercial raw material)). 0.03% (i.e. 0.03% in active ingredient) 'BIOPHILIC ^TM H' by INCI name: Hydrogenated Lecithin (and) C12-16 Alcohols (and) Palmitic Acid (18% by weight of hydrogenated lecithin (active ingredient in the commercial raw material)). 2% (i.e. 0.36% in active ingredient) STEARYL ALCOHOL 1 CHLORPHENESIN 0.27 SODIUM HYDROXIDE 0.025

Ingredients Content (%) Cosmetic purified water QSP 100 VEGETABLE SQUALANE 6 TRI CAPRAT/CAPRYLAT GLYCEROL 6 VEGETABLE GLYCEROL 3 ‘CA D PANTETHEINE S SULFONATE’ from the company Sigma and INCI name: Calcium Pantetheine Sulfonate (and) Aqua (70% by weight of calcium pantetheine sulfonate (active ingredient in the commercial raw material)). 0.7% (i.e. 0.49% in active ingredient) 'LIPOSKIN II' from the company Evonik and named INCI: Hydrogenated Lecithin (and) phytosphingosine (and) Cholesterol (and) C12-16 Alcohols (and) Palmitic Acid (at 0.5% by weight of phytosphingosine (active ingredient in the commercial raw material) and 19.85% by weight of hydrogenated lecithin (active ingredient in the commercial raw material)). 2%
(i.e. 0.01% active ingredient phytosphingosine; and 0.4% active ingredient hydrogenated lecithin) STEARYL ALCOHOL 1 CHLORPHENESIN 0.27 SODIUM HYDROXIDE 0.025

Ingredients Content (%) Cosmetic purified water QSP 100 VEGETABLE SQUALANE 6 TRI CAPRAT/CAPRYLAT GLYCEROL 6 VEGETABLE GLYCEROL 3 ‘CA D PANTETHEINE S SULFONATE’ from the company Sigma and INCI name: Calcium Pantetheine Sulfonate (and) Aqua (70% by weight of calcium pantetheine sulfonate (active ingredient in the commercial raw material)). 0.7% (i.e. 0.49% in active ingredient) ‘KLEPTOSE HP’ from the company Sigma and named INCI: Hydroxypropyl Cyclodextrin (100% by weight of hydroxypropyl cyclodextrin (active ingredient in the commercial raw material)). 0.1% (i.e. 0.1% in active ingredient) 'LIPOSKIN II' from the company Evonik and named INCI: Hydrogenated Lecithin (and) phytosphingosine (and) Cholesterol (and) C12-16 Alcohols (and) Palmitic Acid (at 0.5% by weight of phytosphingosine (active ingredient in the commercial raw material) and 19.85% by weight of hydrogenated lecithin (active ingredient in the commercial raw material)). 2%
(i.e. 0.01% active ingredient phytosphingosine; and 0.4% active ingredient hydrogenated lecithin) STEARYL ALCOHOL 1 CHLORPHENESIN 0.27 SODIUM HYDROXIDE 0.025

Ingredients Content (%) Cosmetic purified water QSP 100 VEGETABLE SQUALANE 6 TRI CAPRAT/CAPRYLAT GLYCEROL 6 VEGETABLE GLYCEROL 3 ‘CA D PANTETHEINE S SULFONATE’ from the company Sigma and INCI name: Calcium Pantetheine Sulfonate (and) Aqua (70% by weight of calcium pantetheine sulfonate (active ingredient in the commercial raw material)). 0.7% (i.e. 0.49% in active ingredient) HYDRANOV PA of the company Codif and INCI name: Aqua (and) Phenethyl Alcohol (and) Sodium Carrageenan (and) Maris Sal (at 0.6% by weight of Sodium carrageenan (active ingredient in the commercial raw material)). 2% (i.e. 0.012% in active ingredient) 'LIPOSKIN II' from the company Evonik and named INCI: Hydrogenated Lecithin (and) phytosphingosine (and) Cholesterol (and) C12-16 Alcohols (and) Palmitic Acid (at 0.5% by weight of phytosphingosine (active ingredient in the commercial raw material) and 19.85% by weight of hydrogenated lecithin (active ingredient in the commercial raw material)). 2%
(i.e. 0.01% active ingredient phytosphingosine; and 0.4% active ingredient hydrogenated lecithin) STEARYL ALCOHOL 1 CHLORPHENESIN 0.27 SODIUM HYDROXIDE 0.025

Ingredients Content (%) Cosmetic purified water QSP 100 VEGETABLE SQUALANE 6 TRI CAPRAT/CAPRYLAT GLYCEROL 6 VEGETABLE GLYCEROL 3 ‘CA D PANTETHEINE S SULFONATE’ from the company Sigma and INCI name: Calcium Pantetheine Sulfonate (and) Aqua (70% by weight of calcium pantetheine sulfonate (active ingredient in the commercial raw material)). 0.7% (i.e. 0.49% in active ingredient) ‘KLEPTOSE HP’ from the company Sigma and named INCI: Hydroxypropyl Cyclodextrin (100% by weight of hydroxypropyl cyclodextrin (active ingredient in the commercial raw material)). 0.1% (i.e. 0.1% in active ingredient) 'HYDRINTENSE MB' from the company Givaudan and INCI name: Aris Aqua (and) Propanediol (and) Porphyridium cruentum Extract (at 0.55% by weight of Porphyridium cruentum extract (active ingredient in the commercial raw material)). 5% (i.e. 0.027% in active ingredient) 'LIPOSKIN II' from the company Evonik and named INCI: Hydrogenated Lecithin (and) phytosphingosine (and) Cholesterol (and) C12-16 Alcohols (and) Palmitic Acid (at 0.5% by weight of phytosphingosine (active ingredient in the commercial raw material) and 19.85% by weight of hydrogenated lecithin (active ingredient in the commercial raw material)). 2%
(i.e. 0.01% active ingredient phytosphingosine; and 0.4% active ingredient hydrogenated lecithin) STEARYL ALCOHOL 1 CHLORPHENESIN 0.27 SODIUM HYDROXIDE 0.025

Ingredients Content (%) Cosmetic purified water QSP 100 VEGETABLE SQUALANE 6 TRI CAPRAT/CAPRYLAT GLYCEROL 6 VEGETABLE GLYCEROL 3 ‘CA D PANTETHEINE S SULFONATE’ from the company Sigma and INCI name: Calcium Pantetheine Sulfonate (and) Aqua (70% by weight of calcium pantetheine sulfonate (active ingredient in the commercial raw material)). 0.7% (i.e. 0.49% in active ingredient) ‘KLEPTOSE HP’ from the company Sigma and named INCI: Hydroxypropyl Cyclodextrin (100% by weight of hydroxypropyl cyclodextrin (active ingredient in the commercial raw material)). 0.1% (i.e. 0.1% in active ingredient) 'HYDRINTENSE MB' from the company Givaudan and INCI name: Aris Aqua (and) Propanediol (and) Porphyridium cruentum Extract (at 0.55% by weight of Porphyridium cruentum extract (active ingredient in the commercial raw material)). 5% (i.e. 0.027% in active ingredient) 'HYDRANOV PA' from the company Codif and INCI name: Aqua (and) Phenethyl Alcohol (and) Sodium Carrageenan (and) Maris Sal (at 0.6% by weight of Sodium carrageenan (active ingredient in the commercial raw material)) . 2% (i.e. 0.012% in active ingredient) 'LIPOSKIN II' from the company Evonik and named INCI: Hydrogenated Lecithin (and) phytosphingosine (and) Cholesterol (and) C12-16 Alcohols (and) Palmitic Acid (at 0.5% by weight of phytosphingosine (active ingredient in the commercial raw material) and 19.85% by weight of hydrogenated lecithin (active ingredient in the commercial raw material)). 2%
(i.e. 0.01% active ingredient phytosphingosine; and 0.4% active ingredient hydrogenated lecithin) STEARYL ALCOHOL 1 CHLORPHENESIN 0.27 SODIUM HYDROXIDE 0.025

Ingredients Content (%) Cosmetic purified water QSP 100 VEGETABLE SQUALANE 6 TRI CAPRAT/CAPRYLAT GLYCEROL 6 VEGETABLE GLYCEROL 3 CA D PANTETHEINE S SULFONATE from the company Sigma and named INCI: Calcium Pantetheine Sulfonate (and) Aqua (70% by weight of calcium pantetheine sulfonate (active ingredient in the commercial raw material)). 0.7% (i.e. 0.49% in active ingredient) KLEPTOSE HP from the company Sigma and named INCI: Hydroxypropyl Cyclodextrin (100% by weight of hydroxypropyl cyclodextrin (active ingredient in the commercial raw material)). 0.1% (i.e. 0.1% in active ingredient) HYDRINTENSE MB from the company Givaudan and INCI name: Aris Aqua (and) Propanediol (and) Porphyridium cruentum Extract (at 0.55% by weight of Porphyridium cruentum extract (active ingredient in the commercial raw material)). 5% (i.e. 0.027% in active ingredient) HYDRANOV PA of the company Codif and INCI name: Aqua (and) Phenethyl Alcohol (and) Sodium Carrageenan (and) Maris Sal (at 0.6% by weight of Sodium carrageenan (active ingredient in the commercial raw material)). 2% (i.e. 0.012% in active ingredient) ‘PHYTOSPHINGOSINE’ from the company Evonik and INCI name: Phytosphingosine (100% by weight of phytosphingosine (active ingredient in the commercial raw material)). 0.03% (i.e. 0.03% in active ingredient) 'BIOPHILIC ^TM H' by INCI name: Hydrogenated Lecithin (and) C12-16 Alcohols (and) Palmitic Acid (18% by weight of hydrogenated lecithin (active ingredient in the commercial raw material)). 2% (i.e. 0.36% in active ingredient) STEARYL ALCOHOL 1 CHLORPHENESIN 0.27 SODIUM HYDROXIDE 0.025

Applied to the skin of the hands and/or face by friction and without rinsing, the creams disclosed in tables 5 to 11 provide an antiviral effect and also make it possible to rehydrate dry and damaged skin. These creams are particularly advantageous for the hygienic cleaning and/or disinfection of the hands and/or face of people with fragile skin or dry skin or those likely to have irritated skin.

Claims (11)

Cosmetic composition comprising, in a physiologically acceptable medium:
- calcium pantetheine sulfonate, and
- at least 2 ingredients chosen from the group consisting of:
• hydroxypropyl cyclodextrin,
• phytosphingosine,
• hydrogenated lecithin,
• sodium carrageenan, and
• an extract of P orphyridium cruentum . Cosmetic composition according to claim 1, characterized in that it comprises in a physiologically acceptable medium:
- calcium pantetheine sulfonate,
- phytosphingosine,
- hydrogenated lecithin, and
- at least 1 ingredient chosen from the group consisting of:
• hydroxypropyl cyclodextrin,
• sodium carrageenan, and
• an extract of Porphyridium cruentum . Cosmetic composition according to claim 1 or claim 2, characterized in that it comprises in a physiologically acceptable medium:
- calcium pantetheine sulfonate,
- hydroxypropyl cyclodextrin,
- phytosphingosine,
- hydrogenated lecithin,
- carrageenan sodium, and
- an extract of Porphyridium cruentum . Cosmetic composition according to any one of claims 1 to 3, characterized in that it is in the form of a cream, oil-in-water or water-in-oil emulsion or multiple emulsion, solution, oil, suspension, gel, milk, lotion, or serum. Cosmetic composition according to any one of claims 1 to 4, characterized in that it further comprises at least one cosmetic adjuvant chosen from the group consisting of antioxidant agents, emollient agents, moisturizing agents, anti-aging agents and their mixtures. Cosmetic composition according to any one of Claims 1 to 5, characterized in that it comprises:
- calcium pantetheine sulfonate in a content ranging from 0.01% to 8% by weight relative to the total weight of the composition,
- at least 2 ingredients chosen from the group consisting of:
• phytosphingosine in a content ranging from 0.001% to 5% by weight relative to the total weight of the composition,
• Hydrogenated lecithin in a content ranging from 0.01% to 10% by weight relative to the total weight of the composition,
• hydroxypropyl cyclodextrin in a content ranging from 0.01% to 5% by weight relative to the total weight of the composition,
• carrageenan sodium in a content ranging from 0.001% to 5% by weight relative to the total weight of the composition, and
• an extract of Porphyridium cruentum in a content ranging from 0.001% to 5% by weight relative to the total weight of the composition . Cosmetic process for cleansing and/or purifying keratin materials, in particular the skin, comprising the application to said keratin materials of at least one layer of cosmetic composition as defined in any one of claims 1 to 6 . Cosmetic process according to claim 7 characterized in that it is a cleansing and/or purifying hand care process. Use of a combination of ingredients as defined in claim 1, in particular the combination of:
- calcium pantetheine sulfonate, and
- at least 2 ingredients chosen from the group consisting of:
• hydroxypropyl cyclodextrin,
• phytosphingosine,
• hydrogenated lecithin,
• sodium carrageenan, and
• an extract of P orphyridium cruentum ,
or preferably the association as defined in claim 2 comprising:
- calcium pantetheine sulfonate,
- phytosphingosine,
- hydrogenated lecithin, and
- at least 1 ingredient chosen from the group consisting of:
• hydroxypropyl cyclodextrin,
• sodium carrageenan, and
• an extract of Porphyridium cruentum ,
or preferably the association as defined in claim 3 comprising:
- calcium pantetheine sulfonate,
- hydroxypropyl cyclodextrin,
- phytosphingosine,
- hydrogenated lecithin,
- carrageenan sodium, and
- an extract of Porphyridium cruentum
as an active association for the hygienic cleaning and/or disinfection of keratin materials, in particular of the skin. Use of calcium pantetheine sulfonate, or of a cosmetic composition comprising it, for the hygienic cleaning and/or disinfection of keratin materials, in particular of the skin. Use according to claim 9 or claim 10, for hygienic cleaning and/or disinfection of hands.